Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors on a Composite Endpoint of HbA1c, Body Weight, and Blood Pressure Reduction: A Nationwide Real World Italian Multicentric Study

NCT04304430 is registered in ClinicalTrials.gov with University of Padova as lead sponsor.

NCT NCT04304430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04304430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors on a Composite Endpoint of HbA1c, Body Weight, and Blood Pressure Reduction: A Nationwide Real World Italian Multicentric Study
Lead sponsor
University of Padova
Phase
Observational
Overall status
Completed
Start date
October 18, 2018
Completion date
February 29, 2020
Enrollment
11,206 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes